

Ref: FOI/GS/ID 9260

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

16 August 2024

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial cancer and non-small cell lung cancer (NSCLC).

*You asked: All questions are shown as received by the Trust.*

*Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment*

*Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:*

- a. Atezolizumab (Tecentriq)*
- b. Avelumab (Bavencio)*
- c. Carboplatin single agent or in any other combination*
- d. Carboplatin with Gemcitabine*
- e. Carboplatin with Paclitaxel*
- f. Cisplatin single agent or in any other combination*
- g. Cisplatin with Gemcitabine*
- h. Cisplatin with Gemcitabine + Nivolumab (Opdivo)*
- i. Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)*
- j. Nivolumab (Opdivo)*
- k. Pembrolizumab (Keytruda)*
- l. Other active systemic anti-cancer therapy*
- m. Palliative care only*

*Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?*

*Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:*

- a. Atezolizumab (Tecentriq)*
- b. Durvalumab (Imfinzi)*
- c. Nivolumab (Opdivo)*

- d. Pembrolizumab (Keytruda)
- e. Chemotherapy
- f. Radiotherapy
- g. Chemotherapy AND Radiotherapy

Trust response:

Q1. Yes

Q2.

a. 2

b. 6

c. 2

d. 5

e. 0

f. 0

g. 11

h. 0

i. 0

j. 1

k. 0

l. 5

m. 14 (This total includes patients having chemo in other categories, above)

Q3. We currently do not have any trials for the treatment of urothelial cancer.

Q4.

a. 8

b. 0

c. 2

d. 20

e. 67 (This total includes patients having chemo in other categories, above)

f. 85

g. 6 (This total excludes patients having RT at this NHS trust and chemo at a different NHS Trust)